Catrix Wound Dressing Receives Reimbursement Approval by the Spanish Ministry of Health.

Business Editors

NEW YORK--(BUSINESS WIRE)--Dec. 3, 2003

Lescarden Inc. (LCAR.OB) announced today that the Spanish Ministry of Health has approved government reimbursement of its Catrix(R) Wound Dressing. The approval ensures that patients will receive either substantial or full reimbursement.

Derived from specially processed bovine tracheal cartilage, Catrix Wound Dressing is approved by the FDA for the management of chronic skin wounds including: decubitus (pressure) ulcers, venous stasis ulcers, diabetic ulcers as well as second-degree burns and post-radiation dermatitis. This segment of the wound care market is estimated at $10 billion worldwide. This figure is expected to grow with the general aging of the population.

Recently published clinical studies have highlighted the beneficial effects of Catrix(R) Wound Dressing in managing pressure ulcers and post-radiation dermatitis when compared to standard treatment protocols.

ICN Iberica, S.A., under an exclusive license agreement with Lescarden distributes Catrix Wound Dressing in Spain, Portugal and Greece.

Lescarden, Inc., is a biotechnology company dedicated to the development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. For more information please contact the Company at 212- 687-1050 or visit www.catrix.com.

For further information, please contact Lescarden Inc. directly at: [phone].